MorphoSys Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

MorphoSys hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$12.44
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von MOR in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von MOR gestiegen sind.

Dividendenrendite im Vergleich zum Markt

MorphoSys Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von MOR im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (MOR)	n/a
Untere 25 % des Marktes (US)	1.6%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (MOR)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von MOR im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von MOR im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von MOR, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da MOR keine Ausschüttungen gemeldet hat.

MorphoSys Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

MorphoSys: Hold Rating Until The Novartis Deal Closes

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis And MorphoSys Are A Perfect Match

Novartis Reportedly in Lead to Acquire MorphoSys

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Morphosys AG Provides Earnings Guidance for the Year 2023

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys AG Provides Earnings Guidance for the Year 2023

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

MorphoSys AG Announces Executive Changes

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

MorphoSys updates Q2 & FY22 guidance below prior provided levels

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

MorphoSys May Not Recover From Adventurous Constellation Buyout

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Health Canada Grants Marketing Authorization for Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MorphoSys AG (XTRA:MOR) completed the acquisition of Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST).

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte and MorphoSys presents new three-year data for blood cancer therapy

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys AG Reaffirms Group Financial Guidance for the Year 2021

MorphoSys reports Q1 results

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

Incyte Corporation and MorphoSys AG Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

MorphoSys AG Announces Management Changes

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Morphosys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab

MorphoSys AG, Annual General Meeting, May 19, 2021

Incyte and MorphoSys AG Announces Data Evaluating Tafasitamab with and Without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented At ASH 2020

MorphoSys AG (MOR) Investor Presentation - Slideshow

Morphosys' Licensee Announces Approval by the European Commission for Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis

MorphoSys Appoints Thomas Biegi as Vice President, Head of Corporate Communications

MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation

Xencor, MorphoSys AG and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

MorphoSys reports Q3 results

MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition

MorphoSys AG Raises Financial Guidance for the Financial Year 2020

Jens Holstein Decides to Step Down as Member of the Morphosys AG's Management Board, Effective December 31, 2020

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen